Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared on LinkedIn:
”The European Medicines Agency (EMA) has accepted our application in collaboration with Astellas Pharma US and Merck for a combination therapy for advanced Urothelial Cancer.
People living with bladder cancer in Europe face poor outcomes at the advanced stage, and innovative therapies are needed. This acceptance marks a significant milestone in our commitment to enhancing treatment options for people with bladder cancer.
Read more here.”
Source: Chris Boshoff/LinkedIn